Hepatic Impairment, Healthy
Conditions
Brief summary
The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.
Detailed description
\[Pharmacokinetic Assessment\] * Measurements \- Tegoprazan and desmethyl tegoprazan (M1) in blood and urine * Endpoints * Primary endpoints: AUClast and Cmax of tegoprazan and M1 * Secondary endpoints: CL/F, t1/2, AUCinf, and fu of tegoprazan; CLrenal and Ae of tegoprazan and M1 \[Safety Assessment\] * Adverse events (AEs) * Clinical laboratory tests * Vital sign * Physical examination * Electrocardiogram (ECG)
Interventions
DRUGTegoprazan 50mg
Oral administration once daily
Sponsors
HK inno.N Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
\[Healthy Control Group\] Inclusion Criteria: * Subjects aged 19 to 70(inclusive) years at the time of signing the informed consent form. * Subjects with a body weight of ≥ 50 kg and ≤ 90 kg at screening. * Subjects with AST, ALT, and ALP levels of ≤ 1.5 × upper limit of the normal reference range (ULN) with total bilirubin \< 2 mg/dL and PT (INR) \< 1.7 at screening. * Subjects who have no chronic disease or any congenital disease within the last 5 years and no pathological symptoms or findings as a result of an internal examination * Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the investigational product(IP).
Exclusion criteria
* Subjects who show symptoms of acute disease at the time of screening. * Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor. * Subjects with history or current evidence of gastrointestinal or hepatobiliary disease which may affect PK evaluation of the IP. * Subjects with history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics). * Subjects with systolic blood pressure (BP) of \< 90 mmHg or \> 160 mmHg, or diastolic BP of \< 50 mmHg or \> 100 mmHg at screening. * Subjects who have received medication or food which may significantly affect absorption, distribution, metabolism, or elimination of study drug within 7 days prior to scheduled study treatment. * Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment. * Subjects who have donated whole blood within 60 days prior to the scheduled study treatment, or has donated blood components or received transfusion within 30 days prior to scheduled study treatment. * Subjects who are unable to use a medically acceptable contraceptive method throughout the study. * Subjects who are determined ineligible for study participation by the investigator for other reasons. \[Subjects with Hepatic Impairment\] Inclusion Criteria: * Subjects with chronic liver disease who meet any of the followings: * Chronic Hepatitis B; * Chronic Hepatitis C; * Alcoholic liver disease; * Non-alcoholic fatty liver disease; or * Liver fibrosis and cirrhosis. * Subjects aged 19 to 70 years (inclusive) at the time of signing the informed consent form. * Subjects with body weight of ≥ 50 kg and ≤ 90 kg with a BMI of ≥ 18.0 kg/m2 and ≤ 30 kg/m2 at screening. * Subjects who meet any of following criteria: * AST, ALT, or ALP level \> 1.5 × ULN at screening; * Total bilirubin ≥ 2 mg/dL at screening; or * PT (INR) ≥ 1.7 at screening. * Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the IP.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic Assessment | Up to 48 hours | AUClast of tegoprazan and M1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic Assessment | Up to 48 hours | CL/F of tegoprazan |
Countries
South Korea
Contacts
Primary ContactYoungshin Keum, R.Ph, Pharm.D
Backup ContactSeokuee Kim, MD, PhD
Outcome results
None listed